A decision aid delivered through tobacco quitlines may improve informed decision making about lung cancer screening, according to study findings.
A decision aid delivered through tobacco quitlines may improve informed decision making about lung cancer screening, according to study findings published in JAMA Network Open.
In previous research, low-dose computed tomography (CT) scans for lung cancer screenings are the only secondary preventive service demonstrated to decrease mortality from lung cancer, with the primary action of preventing lung cancer being to avoid tobacco products.
Researchers conducted a study involving 13 tobacco quitlines to identify callers for screening. In total, 516 quitline clients were enrolled, randomized to receive either a decision aid video called “Lung Cancer Screening: Is It Right for Me?” or a standard lung cancer screening brochure (control group).
The decision aid video outlined eligibility for screening, lung cancer epidemiology and risk factors, and potential harms from screening. In addition, it shows a video of a patient receiving a CT scan.
The results revealed that after 1 week, 67.4% of participants who received the decision aid had reported that they were well prepared to make a screening decision. Conversely, 48.2% of participants who received the standard educational material thought they could make such a decision.
"The quitline clients who received the decision aid were more assured about what was important to them in making the choice about screening and felt better informed," said lead study author Robert Volk, PhD, professor of Health Services Research at the University of Texas MD Anderson Cancer Center, in a statement. "Their knowledge of the harms and benefits of screening was much greater than people who received standard educational information. The clients in the control group were making screening choices while being less prepared and aware of the trade-offs between benefit and harms. We want to head off the uninformed choice and help patients make good, informed decisions about screening."
Additionally, 50% of those who received the decision aid felt informed about their decision choice and 68% reported being clear about their values related to the harmed and benefits of screening, compared to 28.3% and 47.4% of the control group, respectively, according to the results.
"We've demonstrated that this is a very effective way to identify people at risk for lung cancer," said Volk. "There's potential to reach thousands of people who are eligible for screening and already addressing their risk for lung cancer by seeking cessation services."
Reference
Volk RJ, Lowenstein LM, Leal VB, et al. Effect of a patient decision aid on lung cancer screening decision-making by persons who smoke [published online January 31, 2020]. JAMA Netw Open. doi: 10.1001/jamanetworkopen.2019.20362.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More